Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023
07 Dezembro 2023 - 9:46PM
Business Wire
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome
therapeutics company, announced today that preliminary clinical
data from a currently enrolling Phase 1b study of SER-155 study in
adult patients undergoing allogeneic hematopoietic cell
transplantation (allo-HCT) will be presented at the 65th American
Society of Hematology (ASH) Annual Meeting held from December 9-12,
2023, in San Diego, California, USA. SER-155 is an oral, cultivated
live bacterial consortia investigational therapeutic designed to
prevent enteric-derived infections and resulting blood stream
infections, as well as reduce the incidence of graft-versus-host
disease (GvHD) by modulating immune responses in the
gastrointestinal tract.
Poster Presentation Details: Poster Title: Impact
of Investigational Microbiome Therapeutic SER-155 on Pathogen
Domination: Initial Results from a Phase 1b Study in Adults
Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Poster number: 2198 Presenter: Jonathan Peled, MD,
PhD, Memorial Sloan Kettering Cancer Center, New York, NY
Session: 722. Allogeneic Transplantation: Acute and Chronic
GVHD, Immune Reconstitution: Poster I Session Date/Time:
Saturday, December 9, 2023: 5:30pm - 7:30pm EST Location:
San Diego Convention Center, Halls G-H
About SER-155 SER-155 is a consortium of bacterial
strains selected using Seres’ reverse translation discovery and
development platform technologies. SER-155 design incorporated
microbiome biomarker data from human clinical data and preclinical
data from human cell-based assays and in vivo disease models.
SER-155 is intended to restructure the gastrointestinal microbiome
by decreasing the abundance of bacterial pathogens that can harbor
antibiotic resistance, and introducing bacteria that provide
immunomodulatory metabolites that can improve mucosal barrier
integrity and reduce local GI inflammation. These effects are
hypothesized to reduce the likelihood of pathogen translocation and
subsequent bloodstream infection and GvHD.
About Seres Therapeutics Seres Therapeutics, Inc.
(Nasdaq: MCRB) is a commercial-stage company developing novel
microbiome therapeutics for serious diseases. Seres’ lead program,
VOWST™, obtained U.S. FDA approval in April 2023 as the first
orally administered microbiome therapeutic to prevent recurrence of
C. difficile infection (CDI) in adults following antibacterial
treatment for recurrent CDI and is being commercialized in
collaboration with Nestlé Health Science. Seres is evaluating
SER-155 in a Phase 1b study in patients receiving allogeneic
hematopoietic stem cell transplantation. For more information,
please visit www.serestherapeutics.com.
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including the
timing and success of the SER-155 Phase 1b study, and other
statements which are not historical fact.
These forward-looking statements are based on management’s
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
following: we have incurred significant losses, are not currently
profitable and may never become profitable; our need for additional
funding; our limited operating history; the impact of the COVID-19
pandemic; our unproven approach to therapeutic intervention; our
reliance on third parties and collaborators to conduct our clinical
trials, manufacture our product candidates and develop and
commercialize our product candidates, if approved; the unknown
degree and competing factors of market acceptance for VOWST; the
competition we will face; our ability to protect our intellectual
property; and our ability to retain key personnel and to manage our
growth. These and other important factors discussed under the
caption “Risk Factors” in our Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission (SEC), on November 2,
2023, and our other reports filed with the SEC could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views
to change. These forward-looking statements should not be relied
upon as representing our views as of any date subsequent to the
date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231207025255/en/
Investor and Media Contacts: Kevin Mannix
kmannix@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Seres Therapeutics (NASDAQ:MCRB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024